Illumine Investment Management LLC Invests $633,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Illumine Investment Management LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,049 shares of the company’s stock, valued at approximately $633,000.

Several other institutional investors also recently added to or reduced their stakes in AMPH. Aurora Investment Counsel grew its position in Amphastar Pharmaceuticals by 0.4% in the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after purchasing an additional 232 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after buying an additional 398 shares in the last quarter. KBC Group NV raised its holdings in Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of Amphastar Pharmaceuticals by 8.5% during the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after purchasing an additional 801 shares during the period. 65.09% of the stock is owned by institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares in the company, valued at $5,262,392.98. This represents a 5.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares of the company’s stock, valued at $1,333,715.67. This represents a 24.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:AMPH opened at $31.49 on Friday. The company has a 50 day moving average of $35.11 and a 200-day moving average of $42.75. Amphastar Pharmaceuticals, Inc. has a one year low of $30.34 and a one year high of $55.95. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of 10.50, a P/E/G ratio of 2.19 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on AMPH shares. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $50.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.